Loading INCY detail
Loading ticker data...
Loading INCY detail
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N. V. ; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.
The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Chart data unavailable
WILMINGTON, Del.--(BUSINESS WIRE)--1Q Alert.
Incyte Corporation (NASDAQ: INCY - Get Free Report) has received an average recommendation of "Hold" from the twenty-one brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The average 12
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.
Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting.
Diversified Trust Co. cut its stake in Incyte Corporation (NASDAQ: INCY) by 37.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,135 shares of the biopharmaceutical company's stock after selling 8,360 shares during the quarter. Diversified Trust Co.'s holdings in Incyte were
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Executive Leadership Appointments.
Incyte is proactively addressing Jakafi's 2028 patent cliff through robust pipeline diversification and strategic acquisitions. Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong operational performance and funding for R&D. Opzelura posted 33% YoY growth with $678M in 2025 sales, highlighting successful portfolio expansion.
JPMorgan Chase and Co. lessened its stake in Incyte Corporation (NASDAQ: INCY) by 46.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 447,720 shares of the biopharmaceutical company's stock after selling 384,394 shares during the period. JPMorgan Chase and Co. owned
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
Incyte is undervalued due to overemphasis on Jakafi's 2028 US patent cliff, despite a diversifying revenue base and robust pipeline. Non-Jakafi segments grew over 50% YoY in 2025, with management guiding these products to reach $3–4B by 2030, supporting long-term growth. Consensus models an aggressive revenue and EPS decline post-cliff, but slower erosion, pipeline launches, and cost flexibility could materially soften the impact.
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI® (tafasitamab), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one prior line of systemic therapy.
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI® (tafasitamab). The approval follows a supplemental regulatory filing and review by ANVISA under Project Orbis for MINJUVI®, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). 1
Incyte remains attractively valued, trading at 12.5x 2026 EPS, well below sector medians, with 9% EPS and revenue growth expected. Jakafi, currently 60% of revenue, faces patent expiration in 2028; INCY is aggressively developing replacements, targeting non-Jakafi revenue parity by 2030. Four regulatory submissions—Jakafi XR, Monjuvi (DLBCL), povorcitinib (HS), and Opzelura (AD Europe)—could catalyze growth and investor sentiment within 12–18 months.
